Peptidomimetic Drug Screening Service for Cancer

Constructing a large peptidomimetic library for phenotypic screening of various cancers is of great significance for the discovery of anticancer drugs. CD BioSciences provides construction and screening services of multiple peptidomimetic libraries for various cancer types, helping global customers find and research peptidomimetic drugs for cancer treatment.

Overview of Peptidomimetics as Anticancer Drugs

Peptidomimetics are ideal components in cancer therapy because of their advantages in production, such as the possibility of automated chemical synthesis, and ease of modification. The unique advantage of peptidomimetics lies in biological interactions: they provide many possible interaction targets from cancer diagnosis to treatment.

The most influential applications of peptidomimetics in cancer therapy are in three fields: (1) simulating natural interactions between natural proteins or molecules to affect the viability of cancer, (2) targeted therapy or cancer diagnosis, and (3) delivering drugs across biological barriers. We will hopefully see the preclinical research and development of new candidate peptidomimetic drugs.

Advantages of Peptidomimetic Drugs

• Excellent clinical safety and biocompatibility—Degradation products are amino acids-natural substances, which are nutrients or components in cells.
• Can be chemically synthesized—Allows easy introduction of various modifications in a precisely controlled manner.
• Smaller molecular weight—Conducive to penetrating various biofilm barriers.
• Independent of the flow pump—Drug resistance is unlikely to occur.

Our Services

The design and synthesis of peptidomimetics undoubtedly have great potential in drug discovery. In CD BioSciences, we use our top PepDom^TM platform to build a high-throughput peptidomimetic screening library with a capacity of 10¹², providing peptidomimetic screening services for a variety of cancer types.

Our services include but are not limited to:

Our Service Processes

Features of Our Services

CD BioSciences is committed to building a variety of large peptidomimetic libraries to screen drugs for a variety of cancer types. If you are interested in any aspect of peptidomimetic drug development for cancer treatment, please contact us for the best solution.

Reference

1. Kurrikoff, K., Aphkhazava, D., & Langel, Ü. (2019). The future of peptides in cancer treatment. Current Opinion in Pharmacology, 47, 27–32.

Related Services